Tulane University Health Sciences Center, New Orleans, Louisiana 70112, USA.
Am J Gastroenterol. 2010 Oct;105(10):2177-85. doi: 10.1038/ajg.2010.157. Epub 2010 Apr 13.
We sought to compare the histologic response, safety, and tolerability in Latino and non-Latino patients with hepatitis C virus (HCV) genotype 1 treated with peginterferon α-2a plus ribavirin (LATINO study).
LATINO was a prospective, open-label, multicenter study that enrolled 269 Latinos and 300 non-Latinos receiving peginterferon α-2a 180 μg/week and ribavirin 1,000/1,200 mg/day for 48 weeks. Liver biopsies were obtained within 18 months of baseline and at week 72. Improved or worsened liver fibrosis and necroinflammatory activity were assessed by the Ishak-modified histologic activity index scoring system. Efficacy and safety parameters were monitored during treatment and the 24-week follow-up period.
The primary study results published elsewhere showed a higher sustained virologic response (SVR) rate among non-Latinos than Latinos (49% vs. 34%; P<0.001). Paired biopsy data were available for 157 Latinos and 201 non-Latinos. At baseline, more Latinos vs. non-Latinos had alanine aminotransferase (ALT) >3 × the upper limit of normal (20% vs. 18%) and cirrhosis (13% vs. 10%). Both groups experienced improvement in Ishak activity at week 72, although the improvement rates were higher in non-Latinos than Latinos (59% vs. 47%; P=0.03). For both groups, more patients with SVR compared with non-responders had improved Ishak fibrosis scores. In both groups, baseline Ishak activity score (P<0.0001 for both) was predictive of Ishak activity response. Additional predictors in Latinos were age (P=0.0023), body mass index (BMI) (P=0.068), baseline ALT quotient (P=0.031), and baseline Ishak fibrosis scores (P=0.021). There were no significant differences in steatosis changes between the two groups. Adverse events (AEs) and withdrawals due to AEs were more frequent in non-Latinos.
Significant proportions of patients in both groups had histologic response to peginterferon α-2a plus ribavirin. However, histologic response was higher in non-Latinos than in Latinos regardless of virologic response. This study highlights the need for additional strategies to improve virologic response in Latinos.
我们旨在比较拉丁裔和非拉丁裔丙型肝炎病毒 (HCV) 基因型 1 患者接受聚乙二醇干扰素 α-2a 联合利巴韦林治疗的组织学应答、安全性和耐受性 (LATINO 研究)。
LATINO 是一项前瞻性、开放性、多中心研究,共纳入 269 名拉丁裔和 300 名非拉丁裔患者,他们接受每周 180μg 聚乙二醇干扰素 α-2a 和每天 1000/1200mg 利巴韦林治疗 48 周。在基线后 18 个月内和第 72 周时获得肝活检。采用改良的 Ishak 组织学活动指数评分系统评估肝纤维化和坏死性炎症活动的改善或恶化情况。在治疗期间和 24 周随访期间监测疗效和安全性参数。
已在其他地方发表的主要研究结果显示,非拉丁裔患者的持续病毒学应答 (SVR) 率高于拉丁裔患者 (49% vs. 34%;P<0.001)。157 名拉丁裔和 201 名非拉丁裔患者有配对活检数据。基线时,与非拉丁裔患者相比,更多的拉丁裔患者丙氨酸氨基转移酶 (ALT) >3 倍正常值上限 (20% vs. 18%)和肝硬化 (13% vs. 10%)。两组在第 72 周时均观察到 Ishak 活动改善,而非拉丁裔患者的改善率高于拉丁裔患者 (59% vs. 47%;P=0.03)。与非应答者相比,两组中更多的 SVR 患者的 Ishak 纤维化评分有所改善。在两组中,基线 Ishak 活动评分 (均 P<0.0001) 均是 Ishak 活动应答的预测因素。拉丁裔患者的其他预测因素包括年龄 (P=0.0023)、体重指数 (BMI) (P=0.068)、基线 ALT 比值 (P=0.031) 和基线 Ishak 纤维化评分 (P=0.021)。两组间脂肪变性变化无显著差异。非拉丁裔患者的不良事件 (AE) 和因 AE 导致的停药更为频繁。
两组患者均有相当比例的患者对聚乙二醇干扰素 α-2a 联合利巴韦林有组织学应答。然而,无论病毒学应答如何,非拉丁裔患者的组织学应答均高于拉丁裔患者。本研究强调需要采取额外的策略来提高拉丁裔患者的病毒学应答率。